NeuroFinance Human Stress Trial During Financial and Informational Volatility

The NeuroFinance Human Stress Trial (NFHST-2026-001) is a prospective, decentralized observational study designed to evaluate physiologic and behavioral responses associated with exposure to financial market volatility, economic uncertainty, and digitally mediated informational stress environments.

Participants will undergo remote monitoring using commercially available wearable biosensor technologies and digital health platforms. Data collection may include continuous or intermittent monitoring of:

Heart rate variability (HRV) Resting heart rate Sleep duration and sleep efficiency Blood pressure measurements Physical activity metrics Galvanic skin response Voice-based behavioral analytics Optional electrocardiographic monitoring

Environmental and informational exposure datasets may include:

Financial market volatility indices News sentiment datasets Social media exposure metrics Economic uncertainty indicators Behavioral interaction telemetry

Artificial intelligence and machine learning systems may be used for exploratory correlation analyses between physiologic biomarkers and external informational stressors.

No investigational drug or invasive intervention will be administered as part of this observational study.

Optional biologic sampling may include saliva-based inflammatory biomarker collection and participant-reported psychometric assessments.

Primary analyses will evaluate longitudinal changes in physiologic stress-related biomarkers during periods of elevated informational or financial stress exposure.

Secondary analyses will evaluate associations between physiologic variability, behavioral adaptation metrics, sleep disruption, and cognitive performance measures.

The study is intended to support development of digital biomarker methodologies and decentralized monitoring frameworks for stress-related physiologic research.

Inclusion criteria

• Adults age 18 years and older.
• Ability to provide informed consent.
• Willingness and ability to comply with study procedures and remote monitoring requirements.
• Access to a compatible smartphone, tablet, or internet-connected device for decentralized study participation.
• Willingness to utilize wearable physiologic monitoring technologies during the study period.
• Participants with varying degrees of financial market exposure, occupational stress exposure, or digital media exposure are eligible.
• Healthy volunteers and participants with self-reported stress-related symptoms may be enrolled.
• Ability to read and understand English-language consent and study materials.

Exclusion criteria

• Individuals unable or unwilling to provide informed consent.
• Individuals unable to comply with remote monitoring procedures or wearable device usage requirements.
• Active medical or psychiatric instability that, in the opinion of study investigators, may interfere with study participation or data integrity.
• Current incarceration or institutionalization limiting voluntary participation.
• Participation in another interventional clinical trial that may substantially interfere with physiologic monitoring outcomes.
• Any condition that would significantly impair safe study participation as determined by the study investigators.